P U B L I C A T I O N S 2 0 0 2 - 2 0 0 3 Shor-Posner, G , Lecusay, R, Miguez-Burbano, MJ, Morales, G, and Campa, A. Neuroprotection in HIV+ drug users: implications for antioxidant therapy. Journal of Acquired Immune Deficiency Syndromes 31:S84-S88, 2002. Miguez-Burbano, MJ, Archer, H, Rodriguez, M, and Shor-Posner, G . Discontinuation of secondary prophylaxis and the risk of Pneumocystis carinii pneumonia. AIDS 17:140-41, 2003. Shor-Posner, G , Lecusay, R, Miguez, MJ, Moreno-Black, G, Zhang, G, Rodriguez, N, Burbano, X, Baum, M, and Wilkie, F. Psychological burden in the era of HAART: impact of selenium therapy. International Journal of Psychiatry in Medicine 33:55-69, 2003. Miguez, MJ, Shor-Posner, G , Morales, G, Rodriguez, A, and Burbano, X. HIV treatment in drug abusers: impact of alcohol use. Addiction Biology 8:33-37, 2003. Miguez-Burbano, MJ, Burbano, X, Ashkin, D, Pitchenik, A, Allan, R, Pineda, L, Rodriguez, N, and Shor-Posner, G . Impact of tobacco use on the development of opportunistic respiratory infections in HIV seropositive patients on antiretroviral therapy. Addiction Biology 8:39-43, 2003. Perez-Then, E, Peña, R, Tavarez-Roja, M, Peña,C, Quiñonez, S, Buttler, M, Ammann, A, Hernandez, W, Goyanes, M, Miguez, MJ, Shor- Posner, G, and PMTCT Group. Preventing mother-to-child HIV transmission in a developing country: the Dominican Republic experience. Journal of Acquired Immune Deficiency Syndromes 34:506-11, 2003. Singal, R, vanWert, JM, and Ferdinand, L, Jr. Methylation of alpha-type embryonic globin gene alpha pi represses transcription in primary erythroid cells. Blood 100:4217-22, 2002. Singal, R, Wang, SZ, Sargent, T, Zhu, SZ, and Ginder, GD. Methylation of promoter proximal transcribed sequences of an embryonic globin gene inhibits transcription in primary erythroid cells and promotes formation of a cell type-specific methyl cytosine binding complex. Journal of Biological Chemistry 277:1897-1905, 2002. Noss, KR, Singal, R, and Grimes, SR. Methylation state of the prostate specific membrane antigen (PSMA) CpG island in prostate cancer cell lines. Anticancer Research 22:1505-11, 2002. Yaturu, S, Harrara, E, Nopajaroonsri, C, Singal, R, and Gill, S. Gynecomastia attributable to human chorionic gonadotropin-secreting giant cell carcinoma of lung. Endocrine Practice 9:233-35, 2003. Ciarallo, S, Subramaniam, V, Hung, W, Lee, JH, Kotchetkov, R, Sandhu, C, Milic, A, and Slingerland, JM . Altered p27(Kip1) phosphorylation, localization, and function in human epithelial cells resistant to transforming growth factor beta-mediated G(1) arrest. Molecular and Cellular Biology 22:2993-3002, 2002. Liang, J, Zubovitz, J, Petrocelli, T, Kotchetkov, R, Connor, MK, Han, K, Lee, JH, Ciarallo, S, Catzavelos, C, Beniston, R, Franssen, E, and Slingerland, JM . PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27- mediated G1 arrest. Nature Medicine 8:1153-60, 2002. Donovan, JC, Rothenstein, JM, and Slingerland, JM. Non-malignant and tumor-derived cells differ in their requirement for p27Kip1 in transforming growth factor-beta-mediated G1 arrest. Journal of Biological Chemistry 277:41686-92, 2002. Connor, MK, Kotchetkov, R, Cariou, S, Resch, A, Lupetti, R, Beniston, RG, Melchior, F, Hengst, L, and Slingerland, JM . CRM1/Ranmediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis. Molecular Biology of the Cell 14:201-13, 2003 UM/<strong>Sylvester</strong> <strong>Comprehensive</strong> <strong>Cancer</strong> <strong>Center</strong> Scientific Report <strong>2004</strong> 185
P U B L I C A T I O N S 2 0 0 2 - 2 0 0 3 Liang, J and Slingerland, JM . Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2:339-45, 2003. Carastro, LM, Tan, CK, Selg, M, Jack, HM, So, AG, and Downey, KM. Identification of delta helicase as the bovine homolog of HUPF1: demonstration of an interaction with the third subunit of DNA polymerase delta. Nucleic Acids Research 30:2232-43, 2002. Meyer, PR, Matsuura, SE, Tolun, AA, Pfeifer, I, So, AG, Mellors, JW, and Scott, WA. Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 46:1540-5, 2002. Lu, X, Tan, CK, Zhou, JQ, You, M, Carastro, LM, Downey, KM, and So, AG. Direct interaction of proliferating cell nuclear antigen with the small subunit of DNA polymerase delta. Journal of Biological Chemistry 277:24340-5, 2002. Lokeshwar, VB and Soloway, MS. Re: Urine based markers of urological malignancy. Journal of Urology 167:1406-07, 2002. Lokeshwar, VB, Schroeder, GL, Selzer, MG, Hautmann, SH, Posey, JT, Duncan, RC, Watson, R, Rose, L, Markowitz, S, and Soloway, MS. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-stat tests. <strong>Cancer</strong> 95:61-72, 2002. Lokeshwar, VB, Schroeder, GL, Carey, RI, Soloway, MS, and Iida, N. Regulation of hyaluronidase activity by alternative mRNA splicing. Journal of Biological Chemistry 277:33654-63, 2002. Simon, MA, Lokeshwar, VB, and Soloway, MS. Current bladder cancer tests: unnecessary or beneficial? Critical Reviews in Oncology/Hematology 47:91-107, 2003. Posey, JT, Soloway, MS, Ekici, S, Sofer, M, Civantos, F, Duncan, RC, and Lokeshwar, VB. Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. <strong>Cancer</strong> Research 63:2638-44, 2003. Ding, Z, Tang, S-C, Weerasinghe, P, Yang, X, Pater, A, and Liepins, A. The alkaloid sanguinarine is effective against multidrug resistance in human cervical cells via bimodal cell death. Biochemical Pharmacology 63:1415-21, 2002. Ding, Z, Green, AG, Yang, X, Chernenko, G, Tang, S-C, and Pater, A. Retinoic acid inhibits telomerase activity and downregulates expression but does not affect splicing of hTERT: correlation with cell growth rate inhibition in an in vitro cervical carcinogenesis/multidrug-resistance model. Experimental Cell Research 272:185-91, 2002. Ding, Z, Tang, S-C, Weerasinghe, P, Yang, X, Chernenko, G, Pater, A, and Liepins, A. The alkaloid sanguirine is effective against multidrug resistance in human cervical cells via bimodal cell death. Biochemical Pharmacology 63:1415-21, 2002. Tang, S-C. BAG-1, an anti-apoptotic tumor marker. (Invited Review) IUBMB Life 53:99- 105, 2002. Chen, J, Chernenko, G, Xiong, J, and Tang, S- C. Distinct BAG-1 isoforms have different antiapoptotic functions in BAG-1-transfected C33A human cervical carcinoma cell line. Oncogene 21:7050-59, 2002. Tang, S-C. Differential anti-apoptotic function of BAG-1 isoforms in human malignancy. Recent Research and Development in Biophysics and Biochemistry 3:427-44, 2003. Thomas, GR, Regalado, JJ, and McClinton, M. A rare case of mucoepidermoid carcinoma of the nasal cavity. Ear, Nose & Throat Journal 81:519- 22, 2002. 186 UM/<strong>Sylvester</strong> <strong>Comprehensive</strong> <strong>Cancer</strong> <strong>Center</strong> Scientific Report <strong>2004</strong>
- Page 1 and 2:
S C I E N T I F I C R E P O R T 2 0
- Page 3 and 4:
I N T R O D U C T I O N A N D P R O
- Page 5 and 6:
I N T R O D U C T I O N A N D P R O
- Page 7 and 8:
I N T R O D U C T I O N A N D P R O
- Page 9 and 10:
I N T R O D U C T I O N A N D P R O
- Page 11 and 12:
L E A D E R S H I P MULTIDISCIPLINA
- Page 13 and 14:
L E A D E R S H I P EXTERNAL ADVISO
- Page 15 and 16:
C A N C E R P R E V E N T I O N A N
- Page 17 and 18:
C A N C E R P R E V E N T I O N A N
- Page 19 and 20:
C A N C E R P R E V E N T I O N A N
- Page 21 and 22:
C A N C E R P R E V E N T I O N A N
- Page 23 and 24:
C A N C E R P R E V E N T I O N A N
- Page 25 and 26:
C A N C E R P R E V E N T I O N A N
- Page 27 and 28:
C A N C E R P R E V E N T I O N A N
- Page 29 and 30:
C A N C E R P R E V E N T I O N A N
- Page 31 and 32:
C A N C E R P R E V E N T I O N A N
- Page 33 and 34:
C A N C E R P R E V E N T I O N A N
- Page 35 and 36:
C A N C E R P R E V E N T I O N A N
- Page 37 and 38:
C A N C E R P R E V E N T I O N A N
- Page 39 and 40:
C A N C E R P R E V E N T I O N A N
- Page 41 and 42:
C A N C E R P R E V E N T I O N A N
- Page 43 and 44:
C A N C E R P R E V E N T I O N A N
- Page 45 and 46:
C A N C E R P R E V E N T I O N A N
- Page 47 and 48:
C L I N I C A L O N C O L O G Y R E
- Page 49 and 50:
C L I N I C A L O N C O L O G Y R E
- Page 51 and 52:
C L I N I C A L O N C O L O G Y R E
- Page 53 and 54:
C L I N I C A L O N C O L O G Y R E
- Page 55 and 56:
C L I N I C A L O N C O L O G Y R E
- Page 57 and 58:
C L I N I C A L O N C O L O G Y R E
- Page 59 and 60:
C L I N I C A L O N C O L O G Y R E
- Page 61 and 62:
C L I N I C A L O N C O L O G Y R E
- Page 63 and 64:
C L I N I C A L O N C O L O G Y R E
- Page 65 and 66:
C L I N I C A L O N C O L O G Y R E
- Page 67 and 68:
C L I N I C A L O N C O L O G Y R E
- Page 69 and 70:
C L I N I C A L O N C O L O G Y R E
- Page 71 and 72:
C L I N I C A L O N C O L O G Y R E
- Page 73 and 74:
C L I N I C A L O N C O L O G Y R E
- Page 75 and 76:
C L I N I C A L O N C O L O G Y R E
- Page 77 and 78:
C L I N I C A L O N C O L O G Y R E
- Page 79 and 80:
T U M O R C E L L B I O L O G Y P R
- Page 81 and 82:
T U M O R C E L L B I O L O G Y P R
- Page 83 and 84:
T U M O R C E L L B I O L O G Y P R
- Page 85 and 86:
T U M O R C E L L B I O L O G Y P R
- Page 87 and 88:
T U M O R C E L L B I O L O G Y P R
- Page 89 and 90:
T U M O R C E L L B I O L O G Y P R
- Page 91 and 92:
T U M O R C E L L B I O L O G Y P R
- Page 93 and 94:
T U M O R C E L L B I O L O G Y P R
- Page 95 and 96:
T U M O R C E L L B I O L O G Y P R
- Page 97 and 98:
T U M O R C E L L B I O L O G Y P R
- Page 99 and 100:
T U M O R C E L L B I O L O G Y P R
- Page 101 and 102:
T U M O R C E L L B I O L O G Y P R
- Page 103 and 104:
T U M O R C E L L B I O L O G Y P R
- Page 105 and 106:
T U M O R C E L L B I O L O G Y P R
- Page 107 and 108:
T U M O R C E L L B I O L O G Y P R
- Page 109 and 110:
T U M O R C E L L B I O L O G Y P R
- Page 111 and 112:
T U M O R C E L L B I O L O G Y P R
- Page 113 and 114:
T U M O R C E L L B I O L O G Y P R
- Page 115 and 116:
T U M O R C E L L B I O L O G Y P R
- Page 117 and 118:
T U M O R I M M U N O L O G Y P R O
- Page 119 and 120:
T U M O R I M M U N O L O G Y P R O
- Page 121 and 122:
T U M O R I M M U N O L O G Y P R O
- Page 123 and 124:
T U M O R I M M U N O L O G Y P R O
- Page 125 and 126:
T U M O R I M M U N O L O G Y P R O
- Page 127 and 128:
T U M O R I M M U N O L O G Y P R O
- Page 129 and 130:
T U M O R I M M U N O L O G Y P R O
- Page 131 and 132:
T U M O R I M M U N O L O G Y P R O
- Page 133 and 134:
T U M O R I M M U N O L O G Y P R O
- Page 135 and 136:
T U M O R I M M U N O L O G Y P R O
- Page 137 and 138:
T U M O R I M M U N O L O G Y P R O
- Page 139 and 140:
T U M O R I M M U N O L O G Y P R O
- Page 141 and 142:
T U M O R I M M U N O L O G Y P R O
- Page 143 and 144:
V I R A L O N C O L O G Y P R O G R
- Page 145 and 146:
V I R A L O N C O L O G Y P R O G R
- Page 147 and 148: V I R A L O N C O L O G Y P R O G R
- Page 149 and 150: V I R A L O N C O L O G Y P R O G R
- Page 151 and 152: V I R A L O N C O L O G Y P R O G R
- Page 153 and 154: V I R A L O N C O L O G Y P R O G R
- Page 155 and 156: V I R A L O N C O L O G Y P R O G R
- Page 157 and 158: S H A R E D R E S O U R C E S 3) La
- Page 159 and 160: S H A R E D R E S O U R C E S C E L
- Page 161 and 162: S H A R E D R E S O U R C E S D N A
- Page 163 and 164: S H A R E D R E S O U R C E S G E N
- Page 165 and 166: S H A R E D R E S O U R C E S I N F
- Page 167 and 168: S H A R E D R E S O U R C E S P O P
- Page 169 and 170: P U B L I C A T I O N S 2 0 0 2 - 2
- Page 171 and 172: P U B L I C A T I O N S 2 0 0 2 - 2
- Page 173 and 174: P U B L I C A T I O N S 2 0 0 2 - 2
- Page 175 and 176: P U B L I C A T I O N S 2 0 0 2 - 2
- Page 177 and 178: P U B L I C A T I O N S 2 0 0 2 - 2
- Page 179 and 180: P U B L I C A T I O N S 2 0 0 2 - 2
- Page 181 and 182: P U B L I C A T I O N S 2 0 0 2 - 2
- Page 183 and 184: P U B L I C A T I O N S 2 0 0 2 - 2
- Page 185 and 186: P U B L I C A T I O N S 2 0 0 2 - 2
- Page 187 and 188: P U B L I C A T I O N S 2 0 0 2 - 2
- Page 189 and 190: P U B L I C A T I O N S 2 0 0 2 - 2
- Page 191 and 192: P U B L I C A T I O N S 2 0 0 2 - 2
- Page 193 and 194: P U B L I C A T I O N S 2 0 0 2 - 2
- Page 195 and 196: P U B L I C A T I O N S 2 0 0 2 - 2
- Page 197: P U B L I C A T I O N S 2 0 0 2 - 2
- Page 201 and 202: P U B L I C A T I O N S 2 0 0 2 - 2
- Page 203 and 204: P U B L I C A T I O N S 2 0 0 2 - 2
- Page 205 and 206: G L O S S A R Y IFN—interferon IL